Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Shares Repurchased: 2019-2025

  • C4 Therapeutics' Shares Repurchased fell 71.76% to $24,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $373,000, marking a year-over-year increase of 22.70%. This contributed to the annual value of $194,000 for FY2024, which is 76.36% up from last year.
  • Latest data reveals that C4 Therapeutics reported Shares Repurchased of $24,000 as of Q3 2025, which was down 84.52% from $155,000 recorded in Q1 2025.
  • In the past 5 years, C4 Therapeutics' Shares Repurchased registered a high of $155,000 during Q1 2025, and its lowest value of $16,000 during Q3 2023.
  • Over the past 3 years, C4 Therapeutics' median Shares Repurchased value was $89,500 (recorded in 2023), while the average stood at $80,500.
  • As far as peak fluctuations go, C4 Therapeutics' Shares Repurchased soared by 431.25% in 2024, and later crashed by 71.76% in 2025.
  • Over the past 3 years, C4 Therapeutics' Shares Repurchased (Quarterly) stood at $16,000 in 2023, then spiked by 431.25% to $85,000 in 2024, then plummeted by 71.76% to $24,000 in 2025.
  • Its Shares Repurchased was $24,000 in Q3 2025, compared to $155,000 in Q1 2025 and $85,000 in Q3 2024.